全文获取类型
收费全文 | 31027篇 |
免费 | 1562篇 |
国内免费 | 220篇 |
专业分类
耳鼻咽喉 | 215篇 |
儿科学 | 772篇 |
妇产科学 | 267篇 |
基础医学 | 4026篇 |
口腔科学 | 702篇 |
临床医学 | 1936篇 |
内科学 | 7999篇 |
皮肤病学 | 592篇 |
神经病学 | 2252篇 |
特种医学 | 1334篇 |
外科学 | 5541篇 |
综合类 | 143篇 |
预防医学 | 753篇 |
眼科学 | 459篇 |
药学 | 2048篇 |
中国医学 | 53篇 |
肿瘤学 | 3717篇 |
出版年
2023年 | 209篇 |
2022年 | 137篇 |
2021年 | 636篇 |
2020年 | 384篇 |
2019年 | 587篇 |
2018年 | 735篇 |
2017年 | 554篇 |
2016年 | 712篇 |
2015年 | 742篇 |
2014年 | 1035篇 |
2013年 | 1191篇 |
2012年 | 1865篇 |
2011年 | 2086篇 |
2010年 | 1178篇 |
2009年 | 963篇 |
2008年 | 1702篇 |
2007年 | 1940篇 |
2006年 | 1893篇 |
2005年 | 1904篇 |
2004年 | 1835篇 |
2003年 | 1748篇 |
2002年 | 1733篇 |
2001年 | 588篇 |
2000年 | 526篇 |
1999年 | 510篇 |
1998年 | 401篇 |
1997年 | 313篇 |
1996年 | 291篇 |
1995年 | 273篇 |
1994年 | 246篇 |
1993年 | 219篇 |
1992年 | 330篇 |
1991年 | 350篇 |
1990年 | 301篇 |
1989年 | 372篇 |
1988年 | 273篇 |
1987年 | 231篇 |
1986年 | 216篇 |
1985年 | 213篇 |
1984年 | 149篇 |
1983年 | 133篇 |
1982年 | 86篇 |
1981年 | 67篇 |
1979年 | 97篇 |
1978年 | 65篇 |
1977年 | 71篇 |
1974年 | 69篇 |
1973年 | 70篇 |
1972年 | 75篇 |
1969年 | 65篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Iwasa-Inoue Naomi Nomura Hiroyuki Kataoka Fumio Chiyoda Tatsuyuki Yoshihama Tomoko Nanki Yoshiko Sakai Kensuke Kobayashi Yusuke Yamagami Wataru Morisada Tohru Hirasawa Akira Aoki Daisuke 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(2):441-447
International Journal of Clinical Oncology - This study aimed to investigate the clinical benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian,... 相似文献
2.
3.
4.
5.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
6.
Takaki Shimizu Satoshi Kato Satoru Demura Kazuya Shinmura Noriaki Yokogawa Yuki Kurokawa Noritaka Yonezawa Norihiro Oku Ryo Kitagawa Makoto Handa Ryohei Annen Yoshiyuki Okamoto Hideki Murakami Hiroyuki Tsuchiya 《Journal of orthopaedic science》2021,26(3):327-331
BackgroundLocomotive syndrome is a condition of reduced mobility due to problems with locomotive organs. Although lumbar spinal canal stenosis is one of the major diseases constituting locomotive syndrome, only few studies have focused on the association between the two pathologies. We aimed to investigate the effect of surgery on lumbar spinal canal stenosis with respect to locomotive syndrome using various physical function tests, including locomotive syndrome risk tests, before and after surgery.MethodsClinical data of 101 consecutive patients (male = 46; female = 55; mean age, 69.3 years) who underwent surgery for lumbar spinal canal stenosis at our institute were prospectively collected. Results of physical function tests, including stand-up test, two-step test, and 25-Question Geriatric Locomotive Function Scale, and the sagittal vertical axis were evaluated before and 1 year after surgery. The association between several parameters and improvement of risk level in locomotive syndrome was evaluated.ResultsIn the total assessment, 93.1% of cases were in stage 2 and 6.9% in stage 1 preoperatively, while 72.4% were in stage 2, 22.4% in stage 1, and 5.2% in stage 0 at 1 year postoperatively. Postoperative improvement in the total assessment was observed in 28.7% of cases. Several physical function tests and sagittal vertical axis showed significant improvement after surgery. On multiple logistic regression analysis, age >75 years (odds ratio = 10.9, confidence interval = 1.09–109) and postoperative sagittal vertical axis >40 mm (odds ratio = 17.8, confidence interval = 1.78–177) were significant risk factors associated with non-improvement in risk level of locomotive syndrome.ConclusionsSurgical treatment for lumbar spinal canal stenosis improved physical function, including locomotive syndrome. Risk factors associated with non-improvement of locomotive syndrome were later-stage elderly and postoperative sagittal balance impairment. 相似文献
7.
Hiroyuki Kawano Yuko Honda Tatsuo Amano Haruko Okano Rieko Suzuki Masataka Torii Yoshiko Unno Yoshiaki Shiokawa Teruyuki Hirano 《Journal of stroke and cerebrovascular diseases》2019,28(2):399-404
Background
Anticoagulation therapy, particularly subcutaneous heparin therapy, is recommended for cancer-associated thrombosis. However, not starting or discontinuing anticoagulation was not rare. The aim of the present study was to examine the practical issues related to anticoagulation therapy and effects of subcutaneous heparin therapy for cancer-associated stroke.Methods
Patients with cancer-associated stroke in our stroke center between October 2014 and August 2017 who were diagnosed as having acute ischemic stroke based on diffusion-weighted imaging were retrospectively enrolled. Baseline clinical characteristics, heparin injection, reasons for no subcutaneous heparin therapy, and clinical outcomes were collected.Results
A total of 59 patients with cancer-associated stroke (75 ± 10 years old, male 42%) were enrolled. Lung cancer was the most frequently observed cancer (n = 17, 29%), followed by gastric cancer (n = 8, 14%) and pancreatic cancer (n = 8, 14%). Of the 19 patients (32%) who underwent subcutaneous heparin therapy, it was discontinued in 9 (47%), mainly because of patients’ medical conditions (deterioration of cancer or hemorrhagic complication). Ten patients with long-term subcutaneous heparin therapy did not have stroke recurrence. In contrast, among nine patients who discontinued subcutaneous heparin therapy, three (33%) had recurrence of ischemic stroke. Of the 40 patients without subcutaneous heparin therapy, the main reasons for no subcutaneous heparin therapy were the patients’ medical conditions (n = 22, 55%).Conclusions
Although subcutaneous heparin therapy was given to only one third of cancer-associated stroke patients, long-term subcutaneous heparin therapy might prevent recurrence of cancer-associated stroke. 相似文献8.
Akihisa Okumura Harushi Mori Pin Fee Chong Ryutaro Kira Hiroyuki Torisu Sawa Yasumoto Hiroyuki Shimizu Tsuguto Fujimoto Keiko Tanaka-Taya 《Brain & development》2019,41(5):443-451
Objecive
To clarify the neuroimaging findings of children with acute flaccid myelitis during an outbreak of EV-D68 infection.Methods
We performed a detailed review of the spinal and cranial MRI results of 54 children with acute flaccid myelitis. We focused on the range of longitudinal lesions, the localization and appearance of lesions within a horizontal section, Gadolinium-enhancement, and changes over time.Results
All children had longitudinal spinal lesions involving central gray matter. Twenty-six children had lesions spanning the entire spine. Six of them had weakness in all limbs, whereas seven had weakness of only one limb. Thirty-eight children had lesions in both gray and white matter and limb weakness tended to be more severe in these children. During the acute period, spinal lesions showed bilateral ill-defined widespread T2 hyperintensity. During the subacute period, lesions were well defined and confined to the anterior horn. The distribution of limb weakness was correlated with the appearance of lesions during the subacute period. Gadolinium enhancement was performed in 37 children, and enhancement was seen in the cauda equina in 29 children. Enhancement was infrequent within 2?days after onset but was seen in almost all children thereafter. Twenty-two children had brainstem lesions continuous with spinal lesions.Conclusion
Extensive longitudinal spinal lesions were characteristic in children with acute flaccid myelitis. Lesions were usually bilateral and widespread during the acute period, whereas localization to the anterior horn could become obvious. Although enhancement of the cauda equina was often observed, its appearance was sometimes delayed. 相似文献9.
Hitoshi Kohsaka Tsuneyo Mimori Takashi Kanda Jun Shimizu Yoshihide Sunada Manabu Fujimoto Yasushi Kawaguchi Masatoshi Jinnin Yoshinao Muro Shoichiro Ishihara Hiroyuki Tomimitsu Akiko Ohta Takayuki Sumida 《The Journal of dermatology》2019,46(1):e1-e18
Although rheumatologists, neurologists and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of the present study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time. 相似文献
10.